BCT:CC News and Press, Briacell Therapeutics Corp. From 10/03/25

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform ca...

Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell’s Bria-OTS+ platform Bria-OTS+, a novel personalized, off-the-shelf, semi-allogeneic cellular immunotherapy may address urgent unmet medical needs for pat...

A look at the top 10 most actives in Canada Canadian Natural Resources Limited (CNQ) fell 0.1% to $43.03 on volume of 31,507,334 shares Cenovus Energy Inc. (CVE) rose 2.1% to $23.15 on volume of 28,389,355 shares Tilray Brands Inc. (TLRY) rose 24.2% to $1.95 on volume of 20,027,729 shares ...

A look at the top 10 most actives in Canada Great-West Lifeco Inc. (GWO) fell 0.2% to $55.14 on volume of 4,905,987 shares Manulife Financial Corporation (MFC) fell 0.5% to $42.27 on volume of 4,603,807 shares Tilray Brands Inc. (TLRY) rose 17.2% to $1.84 on volume of 3,947,535 shares iSh...

US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+ TM clinical supply and support Phase 1/2a trial in metastatic prostate cancer Expands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to ...

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotechnology company that develops novel immunotherapie...

A look at the top 10 most actives in Canada Chorus Aviation Inc. 6.00% convertible senior unsecured debentures (CHR.DB.B) fell 0.0% to $100.99 on volume of 17,480,000 shares Suncor Energy Inc. (SU) fell 0.3% to $53.91 on volume of 16,909,070 shares TELUS Corporation (T) rose 0.4% to $21.86 ...

PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cance...

PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cance...

TILsRx platform designed to overcome immune suppression and T cell exhaustion to activate tumor-infiltrating lymphocytes (TILs) Multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targets A preferred tolerability profile ...